Tag - CLBS

Markets

Brookline starts Caladrius Biosciences at buy; PT $7

Brookline Capital Markets initiated coverage of Caladrius Biosciences (NASDAQ:CLBS) with a “buy” rating and a price target of $7. The stock was quoted at $2.05, up 12 cents, at mid-day on May 22...

May 22, 2020

Developments

Caladrius Biosciences reports positive data from coronary microvascular dysfunction study

Caladrius Biosciences (NASDAQ:CLBS) reported positive results from its proof-of-concept study of CLBS16 for the treatment of coronary microvascular dysfunction (CMD). CMD is a non-obstructive coronary artery disease...

November 18, 2019

Tag - CLBS

Brookline starts Caladrius Biosciences at buy; PT $7

Caladrius Biosciences reports positive data from coronary microvascular dysfunction study

General

More